PTX-200

Prescient Therapeutics, Ltd. · Phase 1 active Small molecule

At a glance

Generic name	PTX-200
Also known as	Triciribine Phosphate Monohydrate
Sponsor	Prescient Therapeutics, Ltd.
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Study of PTX-200 (Triciribine) Plus Cytarabine in Refractory or Relapsed Acute Leukemia (PHASE1, PHASE2)
PTX-200 and Carboplatin in Ovarian Cancer (PHASE1, PHASE2)
PTX-200, Paclitaxel, Doxorubicin Hydrochloride, and Cyclophosphamide in Treating Patients With Stage IIB-IV Breast Cancer (PHASE1, PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

PTX-200 CI brief — competitive landscape report
PTX-200 updates RSS · CI watch RSS
Prescient Therapeutics, Ltd. portfolio CI